MA58653A1 - Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6 - Google Patents
Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6Info
- Publication number
- MA58653A1 MA58653A1 MA58653A MA58653A MA58653A1 MA 58653 A1 MA58653 A1 MA 58653A1 MA 58653 A MA58653 A MA 58653A MA 58653 A MA58653 A MA 58653A MA 58653 A1 MA58653 A1 MA 58653A1
- Authority
- MA
- Morocco
- Prior art keywords
- activity
- aberrant
- interleukin
- diseases related
- treat diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention se rapporte au domaine de la médecine et concerne un traitement de maladies associées à une activité aberrante l'interleukine-6 et au développement du syndrome de libération de cytokines (choc cytokinique), de préférence un traitement du covid-19, ainsi que d'autres maladies compliquées par une activité aberrante d'interleukine-6 et le développement d'un syndrome de libération de cytokines, ceci en utilisant un composé de 1-(2-(1-méthyl-1?-imidazol-4- yl)éthyl)pipéridine-2,6-dione (i). L'invention permet de créer un nouvel agent médicamenteux efficace pour le traitement de maladies associées au développement du syndrome de libération de cytokines.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2020121363A RU2774928C2 (ru) | 2020-06-26 | Применение производного глутаримида для терапии заболеваний, ассоциированных с аберрантной активностью интерлейкина-6 | |
PCT/RU2021/050170 WO2021262040A1 (fr) | 2020-06-26 | 2021-06-18 | Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA58653A1 true MA58653A1 (fr) | 2023-07-31 |
MA58653B1 MA58653B1 (fr) | 2024-02-29 |
Family
ID=79281595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA58653A MA58653B1 (fr) | 2020-06-26 | 2021-06-18 | Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6 |
Country Status (6)
Country | Link |
---|---|
CN (1) | CN115803026A (fr) |
BR (1) | BR112022026356A2 (fr) |
CL (1) | CL2022003725A1 (fr) |
CO (1) | CO2023000604A2 (fr) |
MA (1) | MA58653B1 (fr) |
WO (1) | WO2021262040A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023177329A1 (fr) * | 2022-03-18 | 2023-09-21 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Utilisation de 1-(2-(1н-imidazol-4-yl)éthyl)pipéridine-2,6-dione pour le traitement de la toux induite par des infections virales |
WO2023249516A1 (fr) * | 2022-06-24 | 2023-12-28 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Nouvelle forme cristalline de 1-[2-(1-méthylimidazol-4-yl)éthyl]perhydroazine-2,6-dione et utilisation pharmaceutique de celle-ci |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2112716A1 (de) * | 1971-03-17 | 1972-10-05 | Thomae Gmbh Dr K | Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester |
DE10002509A1 (de) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
UA115431C2 (uk) * | 2011-10-11 | 2017-11-10 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Застосування глутарилгістаміну для лікування захворювань дихальних шляхів |
CN102432544B (zh) * | 2011-11-17 | 2014-05-21 | 天津医科大学 | 5-取代苄亚甲基咪唑烷-2,4-二酮类衍生物及其应用 |
CN110128406B (zh) * | 2013-04-12 | 2021-08-27 | 制药有限责任公司 | 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法 |
RU2552929C1 (ru) * | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
US10739353B2 (en) * | 2014-12-31 | 2020-08-11 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
EA039391B1 (ru) * | 2017-09-07 | 2022-01-21 | Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" | Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов |
BR112022020814A2 (pt) * | 2020-04-13 | 2022-11-29 | Univ Health Network | Métodos para tratamento de síndrome de liberação de citocina |
CN113582980B (zh) * | 2020-04-30 | 2023-11-24 | 上海科技大学 | 基于杂环和戊二酰亚胺骨架的化合物及其应用 |
-
2021
- 2021-06-18 CN CN202180044905.7A patent/CN115803026A/zh active Pending
- 2021-06-18 MA MA58653A patent/MA58653B1/fr unknown
- 2021-06-18 BR BR112022026356A patent/BR112022026356A2/pt not_active Application Discontinuation
- 2021-06-18 WO PCT/RU2021/050170 patent/WO2021262040A1/fr active Application Filing
-
2022
- 2022-12-22 CL CL2022003725A patent/CL2022003725A1/es unknown
-
2023
- 2023-01-19 CO CONC2023/0000604A patent/CO2023000604A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021262040A1 (fr) | 2021-12-30 |
CO2023000604A2 (es) | 2023-01-26 |
RU2020121363A3 (fr) | 2021-12-27 |
MA58653B1 (fr) | 2024-02-29 |
CL2022003725A1 (es) | 2023-05-19 |
BR112022026356A2 (pt) | 2023-01-17 |
RU2020121363A (ru) | 2021-12-27 |
CN115803026A (zh) | 2023-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA58653A1 (fr) | Utilisation d'un dérivé de glutarimide pour traiter des maladies liées à l'activité aberrante d'interleukine-6 | |
EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
MA41496B1 (fr) | Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
ATE384724T1 (de) | Cyclopropylverbindungen als ccr5 antagonisten | |
DE60323133D1 (de) | Cyclohexylverbindungen als ccr5-antagonisten | |
NO20025601D0 (no) | Arylmetylaminderivater for anvendelse som tryptaseinhibitorer | |
MA40814A1 (fr) | Compositions pharmaceutiques pour thérapie combinée | |
MA51627B1 (fr) | Benzofurane, benzopyrrole, benzothiophène substitués et inhibiteurs du complément structurellement apparentés | |
CR7882A (es) | Compuestos 2-(1H-Indazol-6-ilamino-benzamidas como inhibidores proteinquinasas utiles para el tratamiento de enfermedades oftalmicas | |
HRP20050533A2 (en) | Aminoindazole derivatives and use thereof as kinase inhibitors | |
EP2329842A3 (fr) | Inhibiteurs d'interleukine 1 dans le traitement de maladies | |
TNSN07063A1 (fr) | Utilisations therapeutiques d'inhibiteurs de rtp801 | |
JP2005532372A5 (fr) | ||
MA28435B1 (fr) | Composes d'indazole-carboxamide en tant qu'agonistes de recepteur 5-ht4 | |
MXPA04001187A (es) | Receptores de interleucina-1 en el tratamiento de enfermedades. | |
MA30324B1 (fr) | Benzimidazoles presentant une activite au niveau du recepteur m1 et leurs utilisations en medecine. | |
PE20050389A1 (es) | Compuestos de quinolina y quinoxalina | |
EA200600480A1 (ru) | Имидазопиридинзамещённые тропановые производные, обладающие активностью антагониста ccr5 рецептора, для лечения вируса иммунодефицита человека (вич) и воспаления | |
MY172303A (en) | Compositions and methods of use of phorbol esters | |
CL2004000366A1 (es) | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. | |
EA200201276A1 (ru) | Производные арилметиламина для использования в качестве ингибиторов триптазы | |
MA46229A (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
MX2018013325A (es) | Derivados de adenina como inhibidores de proteína quinasa. | |
EA202191150A1 (ru) | Ингибиторы аминопептидазы а и содержащие их фармацевтические композиции | |
KR20120083356A (ko) | Hiv 감염 치료를 위한 n-히드록시벤즈아미드의 유도체 |